Kornimate/medical-research-clean huggingface dataset:
sensitivity and specificity of the home macular perimeter (hmp)

Conditions: Age Related Macular Degeneration

Summary: the primary objective of this study is to estimate the sensitivity of the hmp test in identifying visual field functional defects in subjects with cnv secondary to amd, and differentiate them from intermediate amd subjects.

it is a one encounter visit in which patients are enrolled and complete the study on the same day. this will allow recruiting and testing of patients with cnv which is a dynamic disease that is most often treated on that same day. following enrollment, patients will go through an examiner supervised tutorial followed by a self-performed hmp examination. in addition patient will undergo an amsler grid examination, biomicroscopy, color fundus photography and fluorescein angiography. the hmp output shall be a test result that can be within or outside normal limits. inherent to the test are reliability criteria which help to determine if the patient performed the test reliably. these consist of false positive and false negative errors. all criteria for normal limits and reliable performance are set prior to study initiation. the outcome measures for the study are the sensitivity in identifying visual functional defects in patients with cnv.

Eligibility criteria:
inclusion criteria: * capable and willing to sign a consent form and participate in the study * subjects with amd related lesions: new onset (up to 60 days) non-treated cnv or intermediate amd patients (defined as the presence of at least one large drusen or more than 20 medium size drusen) * age \>50 years * va with habitual correction \>20/200 in study eye * familiar with computer usage exclusion criteria: * evidence of macular disease other than amd or glaucoma in the study eye * presence of any significant media opacity that precludes a clear view of the macular area as identified in the study eye by biomicroscopy, cfp, or fa * any non-macular related ocular surgery performed within 3 months prior to study entry in the targeted eye * inability to tolerate intravenous fa * ga in the study eye * participation in another study with the exclusion of areds study

Keywords: amd, hmp, php
post-traumatic stress disorder (ptsd) symptom study

Conditions: PTSD

Summary: the primary goals for this investigation are to quantify: (1) fluctuations in ptsd symptom reports when assessed at bi-weekly intervals; (2) change in ptsd symptoms associated with stressful life events; and (3) change in ptsd symptoms associated with perceived social support.

the primary goals for this investigation are to quantify: (1) fluctuations in ptsd symptom reports when assessed at bi-weekly intervals; (2) change in ptsd symptoms associated with stressful life events; and (3) change in ptsd symptoms associated with perceived social support. despite increased sophistication in measurement of ptsd, little is known about the long-term longitudinal course of this disorder or the fluctuation of symptoms over time. because previous studies have focused on the development and persistence of symptoms immediately following a stressor, the course of the chronic disorder has been largely unexplored. although there is evidence of both persistence and fluctuation of ptsd symptom presentation in vietnam veterans, little is known about how much and in what ways symptoms change over time. this investigation will increase understanding of the nature and extent of symptom fluctuation as well as the longitudinal course of ptsd as first steps in determining which variables affect that course and how clinicians might intervene to alter it. aversive life events may constitute one factor that influences the course of chronic ptsd. researchers and clinicians have frequently hypothesized that stressful life events account for much of the variability in course of chronic ptsd; individuals with ptsd may have a compromised ability to cope with stressors, and such events may worsen existing symptoms. social support is another variable thought to affect the course of post-trauma symptomatology. support from other persons has been shown to both promote psychological health in general and to protect against psychological deterioration in times of stress. this investigation will examine aversive life events and perceived social support to determine their relationships over time to symptoms of ptsd.

Eligibility criteria:
inclusion criteria: 1. vietnam vets who served in combat 2. diagnosis of current or lifetime ptsd excluded if severe psychosis, current diagnosis of acute substance dependence, if no stable residence in past 6 months exclusion criteria: actively psychosis, currently suicidal or homicidal, without telephone access, or had experienced substance or alcohol abuse or dependence within the previous six months.

Keywords: combat-related ptsd, vietnam veterans
effectiveness of a hemodynamic-guided treatment strategy to improve blood pressure control

Conditions: Hypertension

Summary: a single-center, single-blind, randomized study to investigate the effectiveness of a hemodynamic-guided treatment strategy to improve blood pressure control

hypertension is a hemodynamic-related disorder characterized by abnormalities of the cardiac output (co) and/or systemic vascular resistance (svr). it is hypothesized that selecting antihypertensive therapy based on patients' hemodynamic profile could lead to more effective blood pressure (bp) control than standard care in a real-world population of hypertensive patients in outpatient setting. a single-center, randomized trial was conducted to include adults with uncontrolled hypertension who seek outpatient care at peking university people's hospital between december 2018 and december 2019 in beijing, china. participants were randomly assigned to the standard care group or the hemodynamic group in a 1:1 ratio. impedance cardiography (icg) was performed with all participants to measure hemodynamic parameters. only physicians in the hemodynamic group were provided with patients' icg findings and a computerized clinical decision support of recommended treatment choices based on patients' hemodynamic profiles. the primary outcomes were the reductions in systolic bp (sbp) and diastolic bp (dbp) levels at the follow-up visit 8(±4) weeks after baseline. secondary outcomes included achievement of bp goal of \<140/ 90 mmhg and the reductions in bp by baseline bp, age, sex, and bmi. the icg device used (hdprotm chm t3002/p3005, designed by beijing li-heng medical technologies, ltd, manufactured by shandong baolihao medical appliances, ltd.) was developed based on improved hardware and advanced digital filtering algorithms, and has been validated versus both invasive thermodilution and non-invasive echocardiography in different settings.

Eligibility criteria:
inclusion criteria: 1. office bp \>= 140/90 mmhg 2. hypertensive patients who were treatment naive or previously treated with 1-3 anti-hypertensives 3. age 18-85, males or females 4. agree to sign informed consent exclusion criteria: 1. having unstable hemodynamics diseases, or had myocardial infarction (mi), heart failure (hf) or chronic kidney disease (ckd) within previous 6 months 2. using large doses of diuretics or beta-blockers (usually refers to double max doses) and can not stop dosing 3. atrial fibrillation (af) or severe arrhythmia 4. severe aortic regurgitation 5. severe thoracic fluids 6. height weight out of ranges: 120-230 cm30-230 kg 7. using more than 3 antihypertensives 8. known secondary hypertension 9. refused to sign informed consent

Keywords: hypertension icg-guided hemodynamic profiling impedance cardiography
coronary computed tomographic angiography for selective cardiac catheterization

Conditions: Coronary Artery Disease

Summary: to determine the effectiveness, safety, and cost efficiency associated with a ccta-guided selective catheterization strategy for stable patients but without known cad and an american heart association/ american college of cardiology class ii indication for non-emergent invasive coronary angiography.

a prospective, randomized controlled multicenter trial to determine the clinical and cost effectiveness of a "selective catheterization" strategy versus a "direct catheterization" strategy for stable patients with suspected but without known cad and clinical indication for non-emergent invasive coronary angiography. subjects in the "selective catheterization" arm will be followed for a primary endpoint of non-inferiority for rates of major adverse cardiac events (mace) as compare to subjects in the "direct catheterization" strategy.

Eligibility criteria:
inclusion criteria 1. age \>18 years 2. patients providing written informed consent 3. scheduled to undergo clinically-indicated non-emergent invasive coronary angiography with an acc/aha class ii indication exclusion criteria 1. known cad (myocardial infarction, pci, cabg) 2. acc/aha class i or iii indication for ica 3. non-cardiac illness with life expectancy \<2 years 4. inability to provide written informed consent 5. concomitant participation in another clinical trial in which subject is subject to investigational drug or device 6. pregnant women 7. allergy to iodinated contrast agent 8. serum creatinine ≥1.5 mg/dl or glomerular filtration rate \<30 ml/min 9. uncontrolled baseline irregular heart rhythm (e.g., atrial fibrillation, etc.) 10. heart rate ≥100 beats per minute 12) systolic blood pressure ≤90 mm hg 13) contraindications to β blockers or nitroglycerin 14) known complex congenital heart disease 15) body mass index \>35

Keywords: coronary artery disease cardiac ct catheterization
cerebral nimodipine concentrations following oral, intra-venous and intra-arterial administration

Conditions: Subarachnoid Hemorrhage, Aneurysmal; Delayed Cerebral Ischemia; Vasospasm, Cerebral

Summary: nimodipine reduces the risk of poor outcome and delayed cerebral ischemia in patients suffering aneurysmal subarachnoid haemorrhage (sah), but its mode of action is unknown. its beneficial effect is assumed to be due its neuroprotective effects by reducing intracellular calcium and thereby cellular apoptosis, but higher concentrations might induce marked systemic hypotension, thereby inducing cerebral ischemia. since several dosing regimes and routes of administration with inconclusive superiority exist and since the target site concentration of nimodipine - the unbound drug concentrations beyond the blood-brain barrier - is still not known, it is reasonable to measure nimodipine concentrations within the blood, cerebrospinal fluid (csf) and interstitial brain tissue following oral, intra-venous and intra-arterial administration and correlate intra-arterial nimodipine administration to measures of cerebral metabolism and oxygenation. therefore, the investigators propose to investigate in 30 patients suffering severe aneurysmal sah and requiring cerebral microdialysis for cerebral neurochemical monitoring: * the ability of nimodipine to penetrate into the brain of neurointensive care patients by comparing exposure in brain, csf and plasma, dependent on the route of administration (i.e. oral, intra-venous, and intra-arterial) and dosing intra-venously (0.5 - 2mg/h) * the impact of orally, intra-venously, and intra-arterially delivered nimodipine on cerebral metabolism, i.e. lactate/pyruvate ratio, pbto2 and transcranial doppler flow velocities * the effect of oral and intra-venous nimodipine on systemic hemodynamic and cardiac parameters, using continuous pulse contour cardiac output (picco) monitoring * the penetration properties of ethanol - as an excipient of nimodipine infusion - into the brain by comparing exposure in brain, csf and plasma and quantifying the neuronal exposure to alcohol dependent on blood levels


Eligibility criteria:
inclusion criteria: * patient age \> 18 years * aneurysmal subarachnoid hemorrhage * sedated and mechanically ventilated * application of brain microdialysis as standard care (due to the severity of subarachnoid haemorrhage or secondary deterioration) * oral, intra-venous or intra-arterial administration of nimodipine due to clinical indication exclusion criteria: * contraindication for nimodipine * no need of intensive care and bedside cerebral microdialysis as standard care * any disease considered relevant for proper performance of the study or risks to the patient, at the discretion of the investigator
efficacy of botox injection of the masticatory muscles in head &neck cancer patients with trismus after radiotherapy

Conditions: Trismus; Head and Neck Cancer; Radiation Therapy Recipient; BOTOX

Summary: trismus is a common side effect in head and neck cancer patients after radiation therapy. this project aims to explore the therapeutic effect of botulinum toxin (botox) injection to the masticatory muscles in the above-mentioned patients. in this project, botulinum toxin will be injected into the masticatory muscles (medial pterygoid and masticatory muscles), combined with oral rehabilitation exercises, to reduce the patient's masticatory muscle tension and spasm. patient's mouth opening range, quality of life, trismus condition and pain will be evaluated to understand its efficacy.


Eligibility criteria:
inclusion criteria: 1. aged over 18 years old; 2. head and neck cancer patients must have completed radiotherapy for at least 3 months; 3. those whose mouth-opening distance is less than or equal to 3.5 cm (the functional cut-off point of trismus) and who have tightness or pain in the masticatory muscles; 4. medical condition is stable; exclusion criteria: 1. those who have undergone surgery on their masticatory muscles; 2. patients with obvious muscle atrophy or complete fibrosis of masticatory muscles ; 3. those with tumor recurrence at the time of admission; 4. those whose vital signs are unstable due to acute illness.
cross -over study to prove bioequivalence between two oral formulations of levonorgestrel

Conditions: Contraception; Contraception, Postcoital

Summary: a single dose, two treatments (postday and opxion), two periods, two sequences, crossover, randomized, prospective design was chosen with a washout of 21 days between the two study periods. treatment groups were balanced with the same number of male healthy volunteers who were randomly assigned to the study drug administration sequences.


Eligibility criteria:
inclusion criteria: * healthy male volunteers age between 18 and 55 years old with normal vital signs, electrocardiogram (ecg), blood chemistry, liver function profile and urinalysis exclusion criteria: * history of illnesses or any organic abnormalities that could affect the results of the study. * history of abuse tobacco or alcohol or regular use of recreational or therapeutic drugs. * subjects that have taken any medication within 14 days or that are in an elimination period of less than 7 half-lives (whichever is longest) before study startup.
oculomotor and vestibular ocular reflex exercises in patients with benign paroxysmal positional vertigo

Conditions: Benign Paroxysmal Positional Vertigo (Disorder)

Summary: the aim of this research is to assess effects of oculomotor and vor exercises on vertigo, dizziness and balance in patients with bppv. randomized controlled trial was conducted at hameed latif hospital, lahore. the sample size 32 participants which were divided into two groups, 16 participants in traditional physical therapy group and 16 in oculomotor and vestibular ocular reflex exercises group. study duration was of 6 months. sampling technique applied was non-probability consecutive sampling technique. only 30-70 years individuals with benign paroxysmal positional vertigo (bppv) were included. tools used in the study are vertigo handicap questionnaire, visual vertigo analogue scale, dizziness handicap inventory, berg balance scale and dynamic gait index. the data was analyzed using spss.

randomized controlled trial was conducted at hameed latif hospital, lahore. the sample size 32 participants which were divided into two groups, 16 participants in traditional physical therapy group and 16 in oculomotor and vestibular ocular reflex exercises group. study duration was of 6 months. sampling technique applied was non-probability consecutive sampling technique. only 30-70 years individuals with benign paroxysmal positional vertigo (bppv) were included. tools used in the study are vertigo handicap questionnaire, visual vertigo analogue scale, dizziness handicap inventory, berg balance scale and dynamic gait index. the data was analyzed using spss.

Eligibility criteria:
inclusion criteria: * patients who have vertigo with posterior canal involvement during dix-hallpike test with or without accompanying nystagmus (objective or subjective bppv). * ability to walk at least 3 meters by itself with or without assistive device * normal vision with or without correction by spectacles or contact lenses exclusion criteria: * patients with other neurologic conditions, orthopedic problems, and uncontrolled metabolic diseases to eliminate confounding factors affecting balance performance * unable to understand and answer a simple verbal command. * previously underwent oculomotor and vestibular ocular exercises. * other vestibular disorders like meniere disease * long-term use of benzodiazepines (more than 20 years). * patients who are already performing structured physical activities such as muscle strengthening exercises, pilates, yoga or high intensity aerobic exercises

Keywords: benign paroxysmal positional vertigo oculomotor exercises vestibular ocular reflex (vor) exercises
a multicentre, double-blind, double-dummy, randomised study of the analgesic efficacy and safety of valdecoxib compared to diclofenac sodium in patients undergoing knee arthroscopy for anterior cruciate ligament (acl) reconstruction

Conditions: Pain, Postoperative

Summary: to demonstrate non-inferiority of valdecoxib 20 mg twice daily (bid) (with an initial loading dose of 40 mg followed by a second dose of 20 mg on the first day only) with diclofenac sodium delayed release 75 mg bid in analgesic efficacy, in subjects undergoing knee arthroscopy procedure for anterior cruciate ligament (acl) reconstruction, when administered for 6 (±1) days.


Eligibility criteria:
inclusion criteria: * patients who had undergone an uncomplicated acl reconstruction procedure and were in satisfactory health were included in the study * in addition, they needed to have a baseline pain intensity of ≥ 50 mm on the vas and "moderate to severe" pain on the categorical scale within 8 hours of the completion of the surgical procedure to be included exclusion criteria: * patient was scheduled to undergo any other surgical procedure, along with the orthopedic procedure, that was expected to produce a greater degree of surgical trauma than the orthopedic procedure alone * the patient was undergoing bilateral knee arthroscopy * the patient used conventional nsaids, cox-2 inhibitors, or tramadol during the 6 hours preceding surgery, during surgery or subsequent to the end of surgery, until randomization * the patient received oxaprozin or piroxicam within one week prior to randomization * the patient was required to take muscle relaxants, tricyclic antidepressants, tranquilizers, sedatives, hypnotics and neuroleptics, in the post operative period after the patient was randomized into the study * the patient had been treated with patient controlled analgesia subsequent to the end of the surgical procedure

Keywords: anterior cruciate ligament, arthroscopy, knee, post-surgical pain
intra-articular injection versus normal rehabilitation therapy on temporomandibular joint dysfunction

Conditions: Temporomandibular Joint Dysfunction

Summary: the goal of this clinical trial is to study about the clinical effect of intra-articular injection on temporomandibular joint dysfunction the main question it aims to answer is: • can intra-articular injection help improve the temporomandibular joint dysfunction participants will be randomly assigned into the experimental group and the control group, all under comprehensive treatment. the experimental group will be given intra-articular injection additionally, the study lasts 15 days for each patient. researchers will compare the assessments between the two groups to see if intra-articular injection can help improve the temporomandibular joint dysfunction

the background of temporomandibular joint dysfunction is that it is one of the common diseases in the oral and maxillofacial region, and it is the most common among temporomandibular joint diseases. it is more prevalent in young adults, with the highest prevalence rate at 20-30 years old. the goal of this clinical trial is to study about the clinical effect of intra-articular injection on temporomandibular joint dysfunction the main question it aims to answer is: • can intra-articular injection help improve the temporomandibular joint dysfunction participants will be randomly assigned into the experimental group and the control group, all under comprehensive treatment. the experimental group will be given intra-articular injection additionally, the study lasts 15 days for each patient. researchers will compare the assessments between the two groups to see if intra-articular injection can help improve the temporomandibular joint dysfunction

Eligibility criteria:
inclusion criteria: * presence of significant temporomandibular disorder clinical symptoms. * meeting the diagnostic criteria for temporomandibular joint dysfunction and confirmed by x-ray examination. * patients voluntarily participate in this study and provide signed informed consent. * normal cognitive function exclusion criteria: * rheumatic, rheumatoid, or other severe systemic diseases. * infectious temporomandibular joint arthritis or joint tumors. * individuals who have recently received joint injection treatment or photodynamic therapy.
factors influencing flu vaccination in primary health care

Conditions: Flu, Human

Summary: this study aims to study the barriers to flu vaccination among at-risk people at the primary health care level in order to increase the vaccination rates as recommended by the world health organization.

people from vulnerable groups (e.g., those diagnosed with diabetes, chronic obstructive pulmonary disease, asthma) are at increased risk of developing complications from infection with influenza virus, that could ultimately result in death. flu vaccination is recommended by many authorities, including the world health organization, as a means to decrease the risk of developing such life-threatening conditions. however, vaccination rates are well below the recommended threshold.

Eligibility criteria:
inclusion criteria: * people 65+ otherwise healthy; * patients of any age diagnosed with at least one of the following conditions: diabetes, asthma, copd, coronary disease or hearth failure; * no history of flu vaccination in the previous year. exclusion criteria: * patients who have been vaccinated against the flu but who have no record of it in the clinical records; * patients with contraindications to flu vaccination; * patients that cannot be reached either by phone or letter.

Keywords: influenza vaccines influenza, human primary health care